Document:

EX-10.9

 Exhibit 10.9 
 BIND BIOSCIENCES, INC. 
 March 20, 2013 

Dr. Gregory Berk 
 332 South McCadden Place

 Los Angeles, California 90020 
  

	 	Re:	Employment Terms 

 Dear Greg: 

BIND Biosciences, Inc. (the “Company”), is pleased to offer you full-time employment as the Company’s Chief Medical
Officer. You will be responsible for such duties as are normally associated with such position or as otherwise determined by the Company. You will report to Scott Minick, the President and Chief Executive Officer of the Company, or such other
individual as the Company may designate (in any case, the “Supervisor”). Your primary place of employment will initially be in the Company’s offices located in Cambridge, Massachusetts; however, you will be excepted to travel
as may be necessary to fulfill your responsibilities. In the course of your employment with Company, you will be subject to and required to comply with all company policies and all applicable laws and regulations. 

You will be paid a base salary at the weekly rate of $6,730.77, subject to required tax withholding and other authorized deductions. Your
base salary will be payable in accordance with the Company’s standard payroll policies and subject to adjustment pursuant to the Company’s policies as in effect from time to time. The vesting and other terms of the agreements governing the
options to purchase shares of the Company’s common stock you have been granted during the course of your service as a consultant of the Company prior to the date of this letter will continue to apply during the period of your employment with
the Company. In addition, the Company will reimburse you for such reasonable moving expenses incurred in connection with the relocation of your primary residence to the Cambridge, Massachusetts area as you and the Company may mutually agree.

 You will be eligible to participate in all of the employee benefits and benefit plans that the Company generally makes
available to its regular full-time employees. In addition, during your employment, you will be eligible for other standard benefits to the extent applicable generally to other similarly situated employees of the Company. The Company reserves the
right to terminate, modify or add to its benefits and benefit plans at any time. 
 The Company requires that, as a full-time
employee, you devote your full business time, attention, skill and efforts to the tasks and duties of your position as assigned by the Company. If you wish to request consent to provide services (for any or no form of compensation) to any other
person or business entity while employed by the Company, please discuss that with your Supervisor in advance of accepting another position. 

 As a condition of employment, you will be required to (1) sign and comply with a
Nondisclosure, Noncompetition and Assignment of Intellectual Property Agreement, a copy of which is attached hereto as Exhibit A (the “NDA”), which, among other things, prohibits unauthorized use or disclosure of Company
proprietary information, (2) sign and return a satisfactory I-9 immigration form and provide sufficient documentation establishing your employment eligibility in the United States of America and (3) provide satisfactory proof of your
identity as required by United States law. By signing below, you represent that your performance of services to the Company will not violate any duty which you may have to any other person or entity (such as a present or former employer or a
governmental authority), including obligations concerning providing services (whether or not competitive) to others, confidentiality of proprietary information and assignment of inventions, ideas, patents or copyrights, and you agree that you will
not do anything in the performance of services hereunder that would violate any such duty. 
 Notwithstanding anything in this
letter to the contrary, your employment with the Company is “at will”. This means that it is not for any specified period of time and can be terminated by you or by the Company at any time, with or without advance notice, and for any or no
particular reason or cause. The Company does, however, request that that you provide at least two weeks’ written notice in the event you decide to resign other than for Good Reason (as defined below). The at-will nature of your employment also
means that your job duties, title and responsibility and reporting level, work schedule, compensation and benefits, as well as the Company’s personnel policies and procedures, may be changed with prospective effect, with or without notice, at
any time in the sole discretion of the Company, subject to the terms of this letter. 
 If the Company terminates your
employment without Cause (as defined below) or you resign your employment for Good Reason (in either event, a “Qualifying Termination”), subject to your execution of a release acceptable to the Company (the
“Release”) within the 30-day period following your Separation from Service (as defined below), the expiration of any revocation period provided in the Release and your continued compliance with the NDA, the Company will pay you an
amount equal to your then-current base salary rate for a period of four (4) months plus one month for each full year of continuous service to the Company up to the date of your termination of employment, not to exceed six (6) months in the
aggregate (the “Severance Amount”); provided that the Severance Amount will be equal to your then-current base salary rate for a period of six (6) months if the Qualifying Termination occurs within the three (3) months
immediately preceding or the twelve (12) months immediately following a Qualified Sale (as defined below). The Severance Amount will be paid in substantially equal installments in accordance with the Company’s ordinary payroll practices
over four (4) months plus one month for each full year of continuous service to the Company up to the date of your termination of employment, not to exceed six (6) months in the aggregate (the “Severance Period”),
beginning on the first payroll date following the date that is 40 days after the date of your Separation from Service; provided that the Severance Period will be six (6) months if the Qualifying Termination occurs within the three
(3) months immediately preceding or the twelve (12) months immediately following a Qualified Sale. In addition, if you timely elect continued group medical insurance coverage pursuant to COBRA, the Company will reimburse you for the
applicable premiums for you and your eligible dependents during the period commencing on the 

  
 2 

 
date of your Separation from Service and ending on the earliest to occur of (a) the final day of the Severance Period, (b) the date you and/or your eligible dependents are no longer
eligible for COBRA and (c) the date you become eligible to receive medical insurance coverage from a subsequent employer. Notwithstanding the foregoing, if the Company determines that it cannot provide such reimbursement of premiums to you
without potentially violating applicable law, the Company shall in lieu thereof provide to you a taxable monthly payment in an amount equal to the monthly COBRA premium that you would be required to pay to continue your group medical insurance
coverage in effect on the date of your termination of employment (based on the premium for the first month of COBRA coverage), which payment will be made regardless of whether you elect COBRA continuation coverage and will commence in the month
following the month in which your Separation from Service occurs and end on the earliest to occur of (x) the final day of the Severance Period, (y) the date you and/or your eligible dependents are no longer eligible for COBRA and
(z) the date you become eligible to receive medical insurance coverage from a subsequent employer. 
 For purposes of this
letter, the Company will have “Cause” to terminate your employment or service upon (i) your failure to substantially perform your duties with the Company or comply with, in any material respect, any of the Company’s
policies to which you are subject; (ii) a determination by the Company that you failed in any material respect to carry out or comply with any lawful and reasonable directive of the Company; (iii) your breach of a material provision of any
agreement between you and the Company; (iv) your conviction, or plea of no contest or nolo contendere, or the imposition of unadjudicated probation on you for any felony or crime involving moral turpitude; (v) your unlawful use
(including being under the influence) or possession of illegal drugs on the Company’s (or any of its affiliates’) premises or while performing your duties and responsibilities for the Company (or any of its affiliates); or (vi) your
commission of an act of fraud, embezzlement, misappropriation, willful misconduct or breach of fiduciary duty against the Company or any of its affiliates. 
 For the sole purpose of determining your right to separation payments and benefits hereunder, your resignation will be for “Good Reason” if you resign your employment immediately
following any of the following: (A) a change in your principal work location despite your stated disagreement with such a change, to a location more than 60 miles from the Company’s current location in Cambridge, Massachusetts (travel for
Company business shall not be deemed a change in principal work location); (B) a material reduction by the Company without your consent in your base salary or benefits (provided, that if the Company’s Board of Directors has determined that
it is in the best interests of the Company to reduce compensation and benefits generally, such reduction shall not constitute Good Reason if (1) the reduction of the salary and benefits is proportionate to the reduction imposed on other
executives of the Company of similar seniority and (2) the reduction does not reduce the salary and benefits by more than 20% below the level then in effect); or (C) a material reduction by the Company without your consent in your duties,
position, title, or responsibilities (unless such reduction occurs after a Qualified Sale in which case a mere change in title or reporting responsibilities will not constitute Good Reason). 

For the purposes of this letter, “Qualified Sale” shall mean the sale of all or substantially all of the assets or
issued and outstanding capital stock of the Company, or merger or consolidation involving the Company in which stockholders of the Company immediately before 

  
 3 

 
such merger or consolidation do not own immediately after such merger or consolidation capital stock or other equity interests of the surviving corporation or entity representing more than fifty
percent (50%) in voting power of capital stock or other equity interests of such surviving corporation or entity outstanding immediately after such merger or consolidation. 

For purposes of this letter, “Separation from Service” means a “separation from service” within the meaning of
Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”). Each installment payment provided under this letter shall at all times be considered a separate and distinct payment for purposes of Section 409A
of the Code. Notwithstanding anything in this letter to the contrary, to the extent required to avoid a prohibited distribution under Section 409A of the Code, the benefits provided under this letter will not be provided to you until the
earlier of (a) the expiration of the six-month period measured from the date of your Separation from Service with the Company or (b) the date of your death. Upon the first business day after expiration of the relevant period, all payments
delayed pursuant to the preceding sentence will be paid in a lump sum and any remaining payments due under this letter will be paid as otherwise provided herein. 
 If you accept this offer, this letter and the NDA shall constitute the complete agreement between you and Company with respect to the terms and conditions of your employment, and the term of the
Consulting Agreement, dated as of May 15, 2012, between you and BIND (the “Consulting Agreement”) will continue until, and expire automatically upon, the date you commence employment with the company as a regular, full-time
employee. Any prior or contemporaneous representations (whether oral or written) pertaining to your employment with the Company not contained in this letter or the NDA, or contrary to those contained in this letter or the NDA, that may have been
made to you are expressly cancelled and superseded by this offer; provided that, for the avoidance of doubt, your obligations under the provisions of Section 5 (Developments) and Section 6 (Confidentiality) of the Consulting
Agreement shall survive. 
 This offer letter shall be interpreted and construed in accordance with the laws of the Commonwealth
of Massachusetts without regard to any conflicts of laws principles. While other terms and conditions of your employment may change in the future, the at-will nature of your employment may not be changed, except in a subsequent letter or written
agreement, signed by you and the Chief Executive Officer of the Company. 
 If you wish to accept employment at the Company
under the terms described above, please sign and date this letter and the NDA and return them to me by fax at (617) 491-0351 or by email at ScottMinick@bindbio.com not later than seven days following the date hereof, after which time this offer
of employment will expire. If you accept our offer, we would like you to commence your employment with us as soon as practicable. 
 If you have any questions, regarding this letter or employment with the Company, please feel free to contact me. We look forward to your favorable reply and to a productive and enjoyable work
relationship. 
 [Signature Page Follows] 

  
 4 

 
			
	Sincerely,
	
	BIND BIOSCIENCES, INC.
		
	By:	 	 /s/ Scott Minick

	Name:	 	Scott Minick
	Title:	 	President & Chief Executive Officer

  

	
	Accepted by:
	
	 /s/ Gregory Berk

	Gregory Berk
	
	 March 20, 2013

	Date:

  
 5 

 BIND BIOSCIENCES, INC. 
 March 20, 2013 
 Dr. Gregory Berk 
 332 South McCadden Place 
 Los Angeles, California 90020 

 

	 	Re:	Relocation expenses 

 Dear Greg:

 Reference is made to that certain letter regarding terms of employment from BIND Biosciences, Inc. (the
“Company”) to you dated as of even date herewith (the “Offer Letter”). This letter confirms the Company’s agreement with you regarding the matters described below. 

Subject to your commencing full-time employment with the Company, the Company will provide support and assistance for the relocation of
you and your family to the Cambridge, Massachusetts area as follows: (i) the Company will reimburse you up to $5,000 for reasonable travel, lodging and ground transportation expenses incurred by you and/or your spouse during 2013 to travel no more
than two (2) times to Cambridge, Massachusetts to look for housing, and (ii) the Company will reimburse your reasonable documented moving expenses incurred during 2013 in connection with your and your family’s relocation to the Cambridge,
Massachusetts area in an amount not to exceed $50,000. You agree to make diligent efforts to relocate to the Cambridge, Massachusetts area in 2013. In the event that you have not relocated to the Cambridge, Massachusetts area by January 1, 2014, the
Company may, but shall not be obligated to, extend the relocation support and assistance described in this letter to reimburse you for expenses incurred during 2014. Documentation acceptable to the Company of all reimbursable expenses must be
submitted to the Company no later than the final day of year during which such expenses are incurred. All reimbursements will be provided no later than 60 days following timely submission of such documentation, and shall be subject to all tax
withholdings which the Company determines are required. You will be ultimately liable and responsible for all taxes owed in connection with any reimbursements provided under this letter, regardless of any action the Company takes with respect to any
tax withholding obligations. 
 In the event you voluntarily terminate your employment with the Company (other than for Good
Reason, as defined in the Offer Letter) prior to the first anniversary of the date you commence full-time employment with the Company, you agree to repay to the Company a prorated portion, based on the number of days actually elapsed between the
date you commenced employment and the date of your termination, of any amounts paid by the Company to you or on your behalf under the terms of this letter. 
 This letter contains all of the understandings and representations between the Company and you regarding the matters described herein and supersedes any prior or contemporaneous representations (whether
written and oral). This letter shall be interpreted and construed in 

			
	 Sincerely,

	
	 BIND BIOSCIENCES, INC.

		
	 By:
	 	 /s/ Scott Minick

	 Name:
	 	 Scott Minick

	 Title:
	 	 President & Chief Executive Officer

  

	
	Accepted by:
	
	 /s/ Gregory Berk

	Gregory Berk
	
	 July 30, 2013

	Date:

 BIND BIOSCIENCES, INC. 
 March 13, 2013 
 Dr. Gregory Berk 

332 S. McCadden Place 
 Los Angeles, California
90020 
 Dear Greg: 
 The purpose of
this letter is to set forth an amendment to each of the following options (collectively, the “Options”) to purchase shares of Common Stock of BIND Biosciences, Inc. (the “Company”) that were granted to you under the
Company’s 2006 Stock Incentive Plan: 
  

									
	 Date of Grant
	  	Number of Shares	 	  	Exercise Price	 
			
	 June 12, 2012
	  	 	292,342	  	  	$	0.96	  
	 October 16, 2012
	  	 	20,000	  	  	$	0.96	  

 Each of the Options is hereby amended to provide for the acceleration in full of the vesting of all shares subject to
such Option upon the first to occur of the following, in each case, after the closing of a Qualified Sale (as defined below) and to the extent the unvested portion of such Option has not been forfeited prior to the applicable date, (a) the date
that is 360 days after the closing of such Qualified Sale, (b) the termination by the Company of your employment with the Company within 360 days after the closing of such Qualified Sale or (c) the termination by you of your employment
with the Company for Good Reason (as defined below) within 360 days after the closing of such Qualified Sale. For purposes hereof, (1) “Qualified Sale” shall mean the sale of all or substantially all of the assets or issued and
outstanding capital stock of the Company, or merger or consolidation involving the Company in which stockholders of the Company immediately before such merger or consolidation do not own immediately after such merger or consolidation capital stock
or other equity interests of the surviving corporation or entity representing more than fifty percent in voting power of capital stock or other equity interests of such surviving corporation or entity outstanding immediately after such merger or
consolidation and (2) “Good Reason” shall mean any termination of your employment by you immediately following any of the following: (a) a change in your principal work location despite your stated disagreement with such a
change, to a location more than 60 miles from the Company’s current location in Cambridge, Massachusetts (travel for Company business shall not be deemed a change in principal work location); (b) a reduction by the Company in your salary
or benefits (provided, that if the Company’s Board of Directors has determined that it is in the best interests of the Company to reduce compensation and benefits generally, such reduction shall not qualify as a termination for Good Reason if
(i) the reduction of the salary and benefits is proportionate to the reduction imposed on other executives of the Company of similar seniority and (ii) the reduction does not reduce the salary and benefits by more than 20% below the level
then in effect); or (c) a reduction by the Company in your duties, position, title, or responsibilities (unless such reduction occurs after a Qualified Sale in which case a mere change in title or reporting responsibilities shall not constitute
Good Reason). 
  

			
	Very truly yours,
	
	BIND BIOSCIENCES, INC.
		
	By:	 	 /s/ Andrew Hirsch

		 	Andrew Hirsch
		 	Chief Financial Officer
	
	AGREED:
	
	 /s/ Gregory Berk

	Gregory Berk10.1-Amendment Agreement

Exhibit 10.1

EXECUTION VERSION

AMENDMENT AGREEMENT (this “Amendment”), dated as of August 7, 2013, to (i) the Credit Agreement among NUANCE COMMUNICATIONS, INC., a Delaware corporation (the “Borrower”), the LENDERS party hereto, MORGAN STANLEY SENIOR FUNDING, INC. (“MSSF”), as administrative agent (the “Successor Agent”), and MSSF and BARCLAYS BANK PLC (“BARCLAYS”), as joint lead arrangers and joint book runners, and the other parties thereto from time to time to the Credit Agreement, dated as of March 31, 2006, as amended and restated as of April 5, 2007 and as further amended and restated on July 7, 2011 (as amended, supplemented, amended and restated or otherwise modified prior to the date hereof, the “Existing Credit Agreement”), among the Borrower, the LENDERS party thereto from time to time, UBS AG, STAMFORD BRANCH, as administrative agent (the “Resigning Agent”), and the other parties thereto from time to time and (ii) the Guarantee and Collateral Agreement dated March 31, 2006  (the “Existing Guarantee and Collateral Agreement”) among the Borrower, each Subsidiary of the Borrower party thereto and the Successor Agent.  Capitalized terms used and not otherwise defined herein shall have the meanings assigned to them in the Existing Credit Agreement.
WHEREAS, the parties hereto wish to, among other things, (a) amend and restate the Existing Credit Agreement in its entirety to (i) replace the outstanding Tranche 2 Revolving Credit Facility with a new revolving credit facility having a longer dated maturity, (ii) extend the maturity date of the Term C Loans, (iii) to replace UBS, AG Stamford Branch as Administrative Agent under the Amended and Restated Credit Agreement (as defined below), and as Administrative Agent under each of the other Loan Document, with MSSF and to effect certain other changes as the described herein and (b) amend the Existing Guarantee and Collateral Agreement to effect certain changes as described herein;
WHEREAS, each Lender who executes and delivers this Amendment as a Tranche 3 Revolving  Lender (as defined in Exhibit A) has agreed to provide Tranche 3 Revolving Facility Commitments to the Borrower in the amount set forth opposite such Lender's name on Schedule 2.01 as set forth in Exhibit B hereto;
WHEREAS, pursuant to Section 9.04(h) of the Existing Credit Agreement, the Borrower may amend the terms of Loans or Commitments in lieu of replacing such Loans or Commitments by requiring any Lenders who do not consent to amend (“Non-Consenting Term C Lenders”) to assign such Loans or Commitments to the Administrative Agent or its designees (collectively, the “New Term C Lenders”), such assignment to be deemed to be automatic pursuant to the terms of Section 9.04(h).
WHEREAS, each Lender including new Lenders that have been assigned Loans by Non-Consenting Term C Lenders pursuant to Section 9.04(h), by executing and delivering this Amendment, has consented to the amendments to be made to the Existing Credit Agreement and the Existing Guarantee and Collateral Agreement;
WHEREAS, Section 9.08 of the Existing Credit Agreement provides that the relevant Loan Parties and the Required Lenders may amend the Existing Credit Agreement, Existing Guarantee and Collateral Agreement and the other Loan Documents for certain purposes;
NOW, THEREFORE, in consideration of the premises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound hereby, agree as follows:
Section 1.Amendment.  

(a)The Existing Credit Agreement is, effective as of the 2013 Amendment Effective Date (as defined below), hereby amended to delete the stricken text (indicated textually in the same manner as the following example: stricken text) and to add the double-underlined text (indicated textually in the same 

1

manner as the following example: double-underlined text) as set forth in Exhibit A hereto (the Existing Credit Agreement as amended hereby, the “Amended and Restated Credit Agreement”).

(b)Each of the Exhibits and Schedules to the Existing Credit Agreement set forth in Exhibit B hereto is, effective as of the 2013 Amendment Effective Date, hereby amended and restated in the form set forth in Exhibit B hereto.

(c)The Existing Guaranty and Collateral Agreement is, effective as of the 2013 Amendment Effective Date, hereby amended as follows (the Existing Guaranty and Collateral Agreement as amended hereby, the “Amended Guaranty and Collateral Agreement”):

(i)The second paragraph of Section 4.01(b) is hereby replaced in its entirety with the following:

“The Administrative Agent is further authorized to file with the United States Copyright Office (or any successor office or any similar office in any other country) such documents as may be reasonably necessary or advisable for the purpose of perfecting, confirming, continuing, enforcing or protecting the Security Interest granted by each Pledgor, without the signature of any Pledgor, and naming any Pledgor or the Pledgors as debtors and the Administrative Agent as secured party.”
(ii) Section 4.05(d) is hereby replaced in its entirety with the following:

“Each Pledgor, either itself or through any agent, employee, licensee or designee, shall (i) inform the Administrative Agent on an annual basis (at the time of delivery of the annual financial statements pursuant to Section 5.04(a) of the Credit Agreement) of each registration and each application made by itself, or through any agent, employee, licensee or designee, for any Patent, Trademark or Copyright with the United States Patent and Trademark Office or the United States Copyright Office filed during the preceding fiscal year, and (ii) execute and file any and all agreements, instruments, documents and papers as are necessary or as the Administrative Agent may reasonably request to evidence the Administrative Agent's security interest in such Copyright (it being understood, for the avoidance of doubt, that no Pledgor shall be required to make any filings with the United States Patent and Trademark Office).”
(d)Each Term C Lender that wishes to continue as a Term C Lender on the 2013 Amendment Effective Dates subject to all of the rights, obligations and conditions thereto under the Amended and Restated Credit Agreement by executing the signature page hereof as a “Consenting Term C Lender” and delivering to the Administrative Agent such signature page prior to 5:00 PM, New York City time on August 5, 2013 (the “Consent Deadline”) (provided that the Borrower in its discretion in consultation with the Administrative Agent may accept any signature page delivered to the Administrative Agent after the Consent Deadline).

(e)Each Non-consenting Term Loan Lender is hereby deemed to have assigned its Term C Loans to the New Term C Lenders immediately prior to the 2013 Amendment Effective Date and such New Term C Lenders hereby consent to the amendments described in clause (1)(a) above by delivering a signature page to this Amendment as a “New Term C Lender,” in each case in accordance with Section 9.04(h) of the Existing Credit Agreement.  The posting of this Amendment to the Term C Lenders hereby serves as the notice to Lenders required pursuant to Section 9.04(h).

(f)A Lender shall become a Tranche 3 Revolving Lender (as defined in Exhibit A) and a holder of Tranche 3 Revolving Commitments (as defined in Exhibit A) subject to all of the rights, obligations and conditions thereto under the Amended and Restated Credit Agreement by executing the signature page hereof as a “Tranche 3 Revolving Lender” and delivering to the Administrative Agent such signature page prior to the Consent Deadline (provided that the Borrower in its discretion in consultation with the Administrative Agent may accept any signature page delivered after the Consent Deadline) stating 

2

that the amount of Tranche 3 Revolving Commitments that such Lender will provide (or such lesser amount as notified to such Lender in writing by the Administrative Agent prior to the 2013 Amendment Effective Date).

(g)The Lenders signing below acknowledge receipt of the notice of resignation from the Resigning Agent, and, as Required Lenders, waive the notice period specified in Section 8.09 of the Credit Agreement and hereby appoint MSSF as successor Administrative Agent under the Credit Agreement as of the 2013 Amendment Effective Date.  The Borrower consents to such appointment.  The Lenders signing below authorize the Resigning Agent and MSSF to enter into a Successor Agent Agreement and all other documents and instruments necessary to assign all of the Loan Documents and liens and security interests created thereunder to MSSF.

Section 2.Representations and Warranties.  The Borrower represents and warrants to the Administrative Agent and each of the Lenders that:

(a)The execution and delivery of this Amendment is within the Borrower's organizational powers and has been duly authorized by all necessary organizational action on the part of the Borrower.  This Amendment has been duly executed and delivered by the Borrower and constitutes, a legal, valid and binding obligation of the Borrower, enforceable in accordance with its terms, subject to applicable bankruptcy, insolvency or similar laws affecting creditors' rights generally, subject to general principles of equity and subject to implied covenants of good faith and fair dealing.  This Amendment will not violate any Requirement of Law in any material respect, will not violate or result in a default or require any consent or approval under any indenture, agreement or other instrument binding upon any Loan Party or its property, or give rise to a right thereunder to require any payment to be made by any Loan Party, except in each case for violations, defaults or the creation of such rights that would not reasonably be expected to result in a Material Adverse Effect.

(b)After giving effect to this Amendment, the representations and warranties set forth in Article III of the Existing Credit Agreement or in any other Loan Document are true and correct in all material respects (except where such representations and warranties expressly relate to an earlier date, in which case such representations and warranties shall have been true and correct in all material respects as of such earlier date).

(c)After giving effect to this Amendment, no Default or Event of Default has occurred and is continuing.

Section 3.Effectiveness.   This Amendment shall become effective on the date (the “2013 Amendment Effective Date”) on which (i) the Administrative Agent shall have received counterparts of this Amendment executed by the Borrower, the Guarantors, MSSF, each Tranche 3 Revolving Lender, each Consenting Term C Lender and each New Term C Lender and (ii) each of the following conditions shall have been satisfied in accordance with the terms thereof:

(a)the representations and warranties set forth in Section 2 hereof shall be true and correct as of the 2013 Amendment Effective Date;

(b)the Borrower shall deliver or cause to be delivered a legal opinion of counsel to the Borrower, together with any additional legal opinions or other documents reasonably requested by the Administrative Agent in connection herewith, in each case dated the 2013 Amendment Effective Date;

(c)the Administrative Agent shall have received a certificate, dated the 2013 Amendment Effective Date and signed by a Responsible Officer of the Borrower, confirming compliance with the conditions precedent set forth in this Section 3 (to the extent satisfaction thereof is not subject to the 

3

discretion of a Secured Party) and Section 4.01 of the Amended and Restated Credit Agreement (to the extent satisfaction thereof is not subject to the discretion of a Secured Party);

(d)MSSF and Barclays, as joint lead arrangers (the “Joint Lead Arrangers”) in connection with this Amendment, shall have been paid such fees as the Joint Lead Arrangers and the Borrower have separately agreed to pursuant to the Engagement and Fee Letter, dated July 30, 2013 among the Joint Lead Arrangers and the Borrower;

(e)The Administrative Agent shall have received, for the account of (i) the Term C Lenders (including the New Term C Lenders), upfront fees in an amount equal to 0.25% of their respective outstanding Term C Loans and (ii) the Tranche 3 Revolving Lenders, upfront fees in an amount equal to 0.375% of their respective Tranche 3 Revolving Facility Commitments;

(f)MSSF, as Administrative Agent, shall have been paid such fees as MSSF and the Borrower have separately agreed to pursuant to the Administrative Agent Fee Letter, dated August 7, 2013 among the MSSF and the Borrower;

(g)the Borrower shall have paid all reasonable out-of-pocket costs and expenses of the Joint Lead Arrangers and the Administrative Agent in connection with the preparation, negotiation and execution of this Amendment (including the reasonable fees and expenses of Cahill Gordon & Reindel llp as counsel to the Joint Lead Arrangers); and

(h)the Administrative Agent, UBS AG, Stamford Branch and the Borrower shall have entered into a Successor Agent Agreement dated as of the 2013 Amendment Effective Date and shall have delivered all documents and prepared all filings contemplated thereby (except as provided in the last paragraph of Section 2).

Section 4.Counterparts.  This Amendment may be executed in any number of counterparts and by different parties hereto on separate counterparts, each of which when so executed and delivered shall be deemed to be an original, but all of which when taken together shall constitute a single instrument.  Delivery of an executed counterpart of a signature page of this Amendment by facsimile or any other electronic transmission shall be effective as delivery of a manually executed counterpart hereof.

Section 5.Applicable Law.  THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.  The provisions of Sections 9.07, 9.11 and 9.15 of the Amended and Restated Credit Agreement shall apply to this Amendment to the same extent as if fully set forth herein.

Section 6.Headings.  The headings of this Amendment are for purposes of reference only and shall not limit or otherwise affect the meaning hereof.

Section 7.Post-Closing Covenant.  To the extent not delivered as of the 2013 Amendment Effective Date, within thirty (30) days after the 2013 Amendment Effective Date, unless waived or extended by the Administrative Agent in its sole discretion, the Borrower shall, or shall cause the applicable Loan Party to, deliver to the Administrative Agent each of the following, in form and substance reasonably satisfactory to the Agent: (i) any amendments, supplements, certificates or other documentation required to reflect the appointment of the Successor Agent and maintain perfection of security interests under existing Foreign Pledge Agreements and (ii) certificates or other instruments representing Equity Interests, together with stock powers or other instruments of transfer with respect thereto endorsed in blank, and all promissory notes or instruments,  together with note powers or other instruments of transfer with respect thereto endorsed in blank, in each case that is required to be pledged pursuant to the Security Documents.

4

Section 8.Effect of Amendment.  Except as expressly set forth herein, (i) this Amendment shall not by implication or otherwise limit, impair, constitute a waiver of or otherwise affect the rights and remedies of the Lenders, the Administrative Agent, the Collateral Agent, any other Agent, any Issuing Bank or the Swingline Lender, in each case under the Existing Credit Agreement or any other Loan Document, and (ii) shall not alter, modify, amend or in any way affect any of the terms, conditions, obligations, covenants or agreements contained in the Existing Credit Agreement or any other provision of either such agreement or any other Loan Document.  Except as expressly set forth herein, each and every term, condition, obligation, covenant and agreement contained in the Existing Credit Agreement or any other Loan Document is hereby ratified and re-affirmed in all respects and shall continue in full force and effect.  Each Loan Party reaffirms its obligations under the Loan Documents to which it is party and the validity of the Liens granted by it pursuant to the Security Documents.  This Amendment shall constitute a Loan Document for purposes of the Existing Credit Agreement and the Existing Guarantee and Collateral Agreement and from and after the 2013 Amendment Effective Date, all references to the Existing Credit Agreement and the Existing Guarantee and Collateral Agreement, as applicable, in any Loan Document and all references in the Existing Credit Agreement and the Existing Guarantee and Collateral Agreement, as applicable, to “this Agreement,” “hereunder,” “hereof” or words of like import referring to the Existing Credit Agreement or the Existing Guarantee and Collateral Agreement, as applicable, shall, unless expressly provided otherwise, refer to the Amended and Restated Credit Agreement or Amended Guaranty and Collateral Agreement, as applicable. Each of the Loan Parties hereby consents to this Amendment and confirms that all obligations of such Loan Party under the Loan Documents to which such Loan Party is a party shall continue to apply to the Amended and Restated Credit Agreement and the Amended Guaranty and Collateral Agreement, as applicable.

[Remainder of page intentionally left blank]

5

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their respective authorized officers as of the day and year first above written.
NUANCE COMMUNICATIONS, INC.
		
	By:
	/s/ Thomas L. Beaudoin                                

Name:    Thomas L. Beaudoin
Title:     Executive Vice President and
Chief Financial Officer
Accentus U.S. Holding, Inc.
Art Advanced Recognition 
Technologies, Inc.
Caere Corporation
Control Systems (USA), Inc.
Dictaphone Corporation
Ditech Networks, Inc.
J.A. Thomas and Associates, Inc.
Nuance Document Imaging, Inc.
Nuance Transcription Services, Inc.
Quadramed Quantim Corporation
Ruetli Holding Corporation
Swype, Inc.
Tegic Communications, Inc.
Telluride, Inc.
Transcend Services, Inc.
VirtuOz, Inc.
Vlingo Corporation
Voice Signal Technologies, Inc.

		
	By:
	/s/ Thomas L. Beaudoin                                 

Name:    Thomas L. Beaudoin
Title:    President and Treasurer
Viecore, LLC
eCopy, LLC
Snapin Software, LLC

By: Nuance Communications, Inc. 
Its: Sole Member

		
	By:
	 /s/ Thomas L. Beaudoin                                     

Name:    Thomas L. Beaudoin
Title:    Executive Vice President and
Chief Financial Officer

[Signature Page to Amendment Agreement]

MORGAN STANLEY SENIOR FUNDING, INC., as Administrative Agent, Collateral Agent and as a New Term C Lender
		
	By:
	/s/ Andrew Earls                                                      

Name:    Andrew Earls
Title:    VP

[Signature Page to Amendment Agreement]

MORGAN STANLEY BANK, N.A., 
as Tranche 3 Revolving Lender
		
	By:
	/s/ Andrew Earls                                                 

Name:    Andrew Earls
Title:    VP

[Signature Page to Amendment Agreement]

MORGAN STANLEY SENIOR FUNDING, INC., as Joint Lead Arranger and Joint Book Runner 
		
	By:
	/s/ Andrew Earls                                                        

Name:    Andrew Earls
Title:    VP

[Signature Page to Amendment Agreement]

BARCLAYS BANK PLC, as Joint Lead Arranger, Joint Book Runner and a Lender
		
	By:
	/s/ Vanessa Roberts                                             

Name:      Vanessa Roberts
Title:      Managing Director

[Signature Page to Amendment Agreement]

    
AMENDMENT AND RESTATEMENT TO THE NUANCE COMMUNICATIONS, INC. CREDIT AGREEMENT AND AMENDMENT TO THE GUARANTEE AND COLLATERAL AGREEMENT
 
THE UNDERSIGNED LENDER:

  o Consents to Amendment 

________________________________________,
(Name of Institution)
By:     ___________________________________________    
Name:    
Title:    
[If a second signature is necessary:
By:    _________________________________________        
Name:    
Title:]

Existing Revolving Facility Commitment amount1: $__________________________
Existing Term Loan C amount1: $__________________________

______________________________________________
1 For informational purposes only. In the event of immaterial discrepancies the Administrative Agent's Register will prevail.

[Signature Page to Amendment Agreement]

Exhibit A

Amended and Restated Credit Agreement

(See Attached)

Exhibit B

Amended and Restated Exhibits and Schedules

Schedule 2.01
	
		
	Tranche 3 Revolving Lenders
	Tranche 3 Revolving Facility Commitments

	Morgan Stanley
	$16,125,000

	Barclays Bank PLC
	$16,125,000

	Credit Suisse AG, Cayman Islands Branch
	$12,000,000

	Wells Fargo Bank, National Association
	$12,000,000

	Citibank, N.A.
	$10,000,000

	Deutsche Bank AG, New York Branch
	$8,750,000

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}]]